Riskpilot← Back to searchSign inGet full accessFFT Pharmaceuticals AB
ABActiveOrg 5569556573Virdings Allé 2Wholesale of other machinery and equipment · NACE 4664Est. 20130 employees
Revenue 2024
SEK 0
EBITDA margin
—
-2% vs 2023
Equity ratio
70.0%
Financial strength
Net profit 2024
SEK 969
-68% vs 2023
| Revenue | SEK 0 | — |
| EBITDA | SEK -48K | -2% |
| Net profit | SEK 969 | -68% |
| Total assets | SEK 79K | +10% |
| Equity | SEK 56K | +2% |
| Employees | 0 | — |
Legal name
FFT Pharmaceuticals AB
Org number
5569556573
Legal form
Aktiebolag
NACE code
4664 · Wholesale of other machinery and equipment
Founded
18 december 2013
Share capital
SEK 54 500
Employees
0
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen
Company purpose
Bolaget skall bedriva forskning och utveckling inom det medicinska området, marknadsföra och försälja medicinska tjänster och produkter ävensom idka annan därmed förenlig verksamhet.
Address
Virdings Allé 2
Email
fredrik.hubinette@klaria.com
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Staff expenses | — | — | — | — | — | — | — | — | — | — |
| EBITDA | −144 | −8 | −17 | −20 | −25 | −33 | −33 | −40 | −47 | −48 |
| Depreciation & amort. | −0 | −0 | −0 | −0 | −0 | −0 | −0 | −0 | — | — |
| EBIT | −144 | −8 | −17 | −20 | −25 | −33 | −33 | −40 | −47 | −48 |
| Net financials | — | — | — | — | 40 | 33 | 30 | — | −0 | −0 |
| Profit before tax | −144 | −8 | −17 | −20 | 15 | 0 | −3 | 5 | 3 | 1 |
| Tax | −0 | −0 | −0 | −0 | −0 | −0 | −0 | −0 | — | — |
| Net profit | −144 | −8 | −17 | −20 | 15 | 0 | −3 | 5 | 3 | 1 |
| Item | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | 2 188 | 704 | 3 087 | 576 | 73 | 66 | 61 | 67 | 72 | 79 |
| Equity | 188 | 180 | 2 548 | 35 | 50 | 50 | 47 | 52 | 55 | 56 |
| Long-term debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | — | — |
| Short-term debt | 2 000 | 524 | 539 | 541 | 23 | 16 | 14 | 15 | 18 | 24 |
| Total debt | 2 000 | 524 | 539 | 541 | 23 | 16 | 14 | 15 | 18 | 24 |
EBITDA margin
-4795400.0%
This company
15.8%
Market median
-30350733% vs market
20152024
Equity ratio
70.0%
This company
38.2%
Market median
+83% vs market
20152024
Return on equity
1.7%
This company
18.4%
Market median
-91% vs market
20152024
Net profit margin
96900.0%
This company
8.1%
Market median
+1196196% vs market
20152024
Asset turnover
0.00×
This company
1.12×
Market median
-100% vs market
20152024
Debt / equity
0.43×
This company
0.62×
Market median
+31% vs market
20152024
- Annual report 2024Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Bolagsverket / SCB · Period 2020-01-01 – 2020-12-31
- Annual report 2019Filed via Bolagsverket / SCB · Period 2019-01-01 – 2019-12-31
- Annual report 2018Filed via Bolagsverket / SCB · Period 2018-01-01 – 2018-12-31
- Annual report 2017Filed via Bolagsverket / SCB · Period 2017-01-01 – 2017-12-31
- Annual report 2016Filed via Bolagsverket / SCB · Period 2016-01-01 – 2016-12-31
- Annual report 2015Filed via Bolagsverket / SCB · Period 2015-01-01 – 2015-12-31
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
EN Chief Auditor | Chief Auditor | 2020 | — | — |
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
| Board of Directors | 2022 | — | — | |
| Deputy Board Member | 2022 | — | — | |
| Deputy Board Member | 2020 | — | — |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
Klaria AB | Company | 100.0% | 100.0% | 0001 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
Klaria Pharma Holding AB (publ)
FFT Pharmaceuticals AB Board members of FFT Pharmaceuticals AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Eric Niklas Nordström | Chief Auditor | 0 companies |
| Claes Fredrik Hübinette | Board of Directors | 0 companies |
| Charles Scott Boyer | Deputy Board Member | 0 companies |
| Susan Elisabet Suchdev | Deputy Board Member | 0 companies |